[Efficacy and safety of Xiyanping injection combined with azithromycin in treating mycoplasma pneumonia of children: Meta-analysis].

To systemically evaluate the safety and efficacy of Xiyanping injection combined with azithromycin in the treatment of mycoplasmal pneumonia in children. PubMed, Wanfang Data, CNKI, VIP and CBM were used to search for the clinical randomized controlled trials on Xiyanping injection combined with azithromycin in the treatment of mycoplasmal pneumonia in children from database establishment to July, 2017. The papers were screened according to the established inclusion and exclusion criteria, and then the quality of the included studies was evaluated to extract valid data for Meta-analysis by using Revman 5.3 software. A total of 31 clinical randomized controlled trials were included, involving 2 881 patients. Meta-analysis showed that as compared with azithromycin alone, the combination of azithromycin with azithromycin had obvious advantages in the total effective rate（OR=5.42,95%CI[3.98,7.38],P<0.000 01）, fever clearance time（MD=-1.29,95%CI[-1.51,-1.08],P<0.000 01）, cough disappearance time （MD=-1.72,95%CI[-1.99,-1.46],P<0.000 01）, lung wet rales disappearance time（MD=-1.51,95%CI[-1.88,-1.14],P<0.000 01）, chest X-ray recovery time（MD=-2.72,95%CI[-3.82,-1.63],P<0.000 01）, shortening the hospital stay（MD=-1.88,95%CI[-2.26,-1.50],P<0.000 01）, reducing the incidence of adverse reactions（MD=0.51,95%CI[0.33,0.79],P=0.002）, and other aspects, with statistically significant difference. Based on the existing evidences, Xiyanping injection combined with azithromycin in the treatment of mycoplasmal pneumonia in children can significantly improve the overall clinical efficiency, shorten the hospital stay and reduce the incidence of adverse reactions. However, the clinical trials of existing small randomized controlled trials have low quality of methodology and require a large sample of high quality clinical trials for further validation.